Evidence map›Paper›PMID 36408222›Full record

ArticleFrontiers in pharmacology2022

Supercritical fluid extract of

Doudou Hao, Jia Liu, Ziyou Guo, Jiajia Chen, Tingting Li, Xin Li, Kai Mei, Lingmin Wang, Xinyi Wang, Qing Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Inhibitory Effect of Aconitine on Colorectal Cancer Malignancy via Inducing Apoptosis and Suppression of Cell Motion.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Doudou HaoSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Jia LiuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Ziyou GuoSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Jiajia ChenSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Tingting LiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Xin LiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Kai MeiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Lingmin WangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Xinyi WangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Qing WuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin-based chemotherapy regimens are recommended for patients with advanced colorectal cancer (CRC). However, oxaliplatin (OXA) can cause toxic side effects at the recommended dosage. Therefore, it is necessary to find new drug candidates that can synergize with OXA and thereby lower the OXA dose while still maintaining its efficacy.

Indexed as

Angelica sinensiscolorectal cancercombination therapyoxaliplatintraditional Chinese medicine

Identifiers

PMID36408222
PMCPMC9672077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.